Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ACAD's Cash to Debt is ranked higher than
96% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. ACAD: No Debt )
ACAD' s 10-Year Cash to Debt Range
Min: 1.93   Max: No Debt
Current: No Debt

Equity to Asset 0.95
ACAD's Equity to Asset is ranked higher than
97% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. ACAD: 0.95 )
ACAD' s 10-Year Equity to Asset Range
Min: -2.5   Max: 0.96
Current: 0.95

-2.5
0.96
Interest Coverage No Debt
ACAD's Interest Coverage is ranked higher than
63% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACAD: No Debt )
ACAD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 118.35
M-Score: 2.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -77048.76
ACAD's Operating margin (%) is ranked lower than
51% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. ACAD: -77048.76 )
ACAD' s 10-Year Operating margin (%) Range
Min: -77691.67   Max: 35.82
Current: -77048.76

-77691.67
35.82
Net-margin (%) -76425.62
ACAD's Net-margin (%) is ranked lower than
51% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. ACAD: -76425.62 )
ACAD' s 10-Year Net-margin (%) Range
Min: -77062.5   Max: 35.93
Current: -76425.62

-77062.5
35.93
ROE (%) -30.07
ACAD's ROE (%) is ranked higher than
74% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. ACAD: -30.07 )
ACAD' s 10-Year ROE (%) Range
Min: -138.68   Max: 72.43
Current: -30.07

-138.68
72.43
ROA (%) -29.09
ACAD's ROA (%) is ranked higher than
72% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. ACAD: -29.09 )
ACAD' s 10-Year ROA (%) Range
Min: -78.95   Max: 34.38
Current: -29.09

-78.95
34.38
ROC (Joel Greenblatt) (%) -17296.66
ACAD's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. ACAD: -17296.66 )
ACAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21643.52   Max: 2028.76
Current: -17296.66

-21643.52
2028.76
Revenue Growth (3Y)(%) -100.00
ACAD's Revenue Growth (3Y)(%) is ranked higher than
56% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. ACAD: -100.00 )
ACAD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 73.1
Current: -100

-100
73.1
EBITDA Growth (3Y)(%) 30.70
ACAD's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. ACAD: 30.70 )
ACAD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -42.6   Max: 30.7
Current: 30.7

-42.6
30.7
EPS Growth (3Y)(%) 29.20
ACAD's EPS Growth (3Y)(%) is ranked higher than
92% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ACAD: 29.20 )
ACAD' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.3   Max: 111.5
Current: 29.2

-55.3
111.5
» ACAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ACAD Guru Trades in Q1 2014

Ron Baron 492,442 sh (New)
Steven Cohen 1,153,694 sh (+574.44%)
Andreas Halvorsen 3,598,407 sh (+36.79%)
» More
Q2 2014

ACAD Guru Trades in Q2 2014

Andreas Halvorsen 4,757,878 sh (+32.22%)
Steven Cohen 1,082,000 sh (unchged)
Ron Baron 437,000 sh (-11.26%)
» More
Q3 2014

ACAD Guru Trades in Q3 2014

Paul Tudor Jones 10,748 sh (New)
Ron Baron 502,100 sh (+14.90%)
Andreas Halvorsen 4,324,890 sh (-9.10%)
Steven Cohen 925,000 sh (-14.51%)
» More
Q4 2014

ACAD Guru Trades in Q4 2014

Steven Cohen 1,018,600 sh (+10.12%)
Andreas Halvorsen 2,956,266 sh (unchged)
Paul Tudor Jones Sold Out
Ron Baron 497,530 sh (-0.91%)
Andreas Halvorsen 2,956,266 sh (-31.65%)
» More
» Details

Insider Trades

Latest Guru Trades with ACAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 166.67
ACAD's Forward P/E is ranked higher than
86% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACAD: 166.67 )
N/A
P/B 10.80
ACAD's P/B is ranked higher than
56% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. ACAD: 10.80 )
ACAD' s 10-Year P/B Range
Min: 0.48   Max: 16.77
Current: 10.8

0.48
16.77
P/S 26726.90
ACAD's P/S is ranked lower than
53% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. ACAD: 26726.90 )
ACAD' s 10-Year P/S Range
Min: 0   Max: 3894
Current: 26726.9

0
3894
EV-to-EBIT -30.88
ACAD's EV-to-EBIT is ranked higher than
87% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACAD: -30.88 )
ACAD' s 10-Year EV-to-EBIT Range
Min: -72.2   Max: 6.3
Current: -30.88

-72.2
6.3
Current Ratio 20.50
ACAD's Current Ratio is ranked higher than
96% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. ACAD: 20.50 )
ACAD' s 10-Year Current Ratio Range
Min: 2.15   Max: 26.99
Current: 20.5

2.15
26.99
Quick Ratio 20.50
ACAD's Quick Ratio is ranked higher than
96% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ACAD: 20.50 )
ACAD' s 10-Year Quick Ratio Range
Min: 2.15   Max: 26.99
Current: 20.5

2.15
26.99
Days Sales Outstanding 2.00
ACAD's Days Sales Outstanding is ranked higher than
99% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. ACAD: 2.00 )
ACAD' s 10-Year Days Sales Outstanding Range
Min: 239.08   Max: 2932.17
Current: 2

239.08
2932.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.90
ACAD's Price/Net Cash is ranked higher than
78% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. ACAD: 10.90 )
ACAD' s 10-Year Price/Net Cash Range
Min: 0.69   Max: 12.75
Current: 10.9

0.69
12.75
Price/Net Current Asset Value 10.90
ACAD's Price/Net Current Asset Value is ranked higher than
76% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. ACAD: 10.90 )
ACAD' s 10-Year Price/Net Current Asset Value Range
Min: 0.66   Max: 12.56
Current: 10.9

0.66
12.56
Price/Tangible Book 10.80
ACAD's Price/Tangible Book is ranked higher than
62% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. ACAD: 10.80 )
ACAD' s 10-Year Price/Tangible Book Range
Min: 0.63   Max: 13.63
Current: 10.8

0.63
13.63
Price/DCF (Projected) 32.70
ACAD's Price/DCF (Projected) is ranked higher than
89% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACAD: 32.70 )
ACAD' s 10-Year Price/DCF (Projected) Range
Min: 31.13   Max: 31.13
Current: 32.7

Earnings Yield (Greenblatt) -3.20
ACAD's Earnings Yield (Greenblatt) is ranked higher than
77% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ACAD: -3.20 )
ACAD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.2   Max: 51153
Current: -3.2

-3.2
51153

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DR6.Germany,
ACADIA Pharmaceuticals Inc was incorporated in Vermont in 1993 as Receptor Technologies, Inc. The Company reincorporated in Delaware in 1997. It is a biopharmaceutical Company engaged in the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Pimavanserin is a new chemical entity that the Company discovered and has advanced to Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Parkinsons disease psychosis is a debilitating disorder that develops in up to 60 percent of patients with Parkinsons disease. The Company has completed a Phase II trial with pimavanserin as a co-therapy in schizophrenia and has established plans for a future Phase II feasibility study to explore the use of pimavanserin as a treatment for Alzheimers disease psychosis. In collaboration with Allergan, it has discovered and is developing small molecule product candidates for the treatment of chronic pain. Chronic pain is a common form of persistent pain that may be related to a number of medical conditions and is often resistant to treatment. Allergan has conducted several Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a human visceral pain trial and efficacy signals in two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome. The Company has discovered and, in collaboration with Allergan, is developing a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the second leading cause of blindness in the world. This program has reached Phase I development. ACADIA and R-SAT are company's registered trademarks. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. It is subject to federal, state and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.
» More Articles for ACAD

Headlines

Articles On GuruFocus.com
Acadia Has Tough Road Ahead With Nuplazid Success Mar 15 2015 
Analysts Remain Bullish on Acadia Pharma Despite Drug Approval Delay Mar 13 2015 
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013 
comment on ACAD Mar 02 2013 
ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 05 2009 
ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009 Jul 29 2009 
ACADIA Pharmaceuticals Inc. Reports Operating Results (10-Q) May 12 2009 

More From Other Websites
Most active Nasdaq-traded stocks Mar 31 2015
Nasdaq stocks posting largest percentage decreases Mar 31 2015
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant Mar 30 2015
IMPORTANT ANNOUNCEMENT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Federal... Mar 27 2015
ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors Mar 26 2015
ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors Mar 26 2015
ACADIA PHARMACEUTICALS INC Files SEC form 8-K/A, Change in Directors or Principal Officers Mar 26 2015
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Change... Mar 25 2015
Superconductor Technologies, Inc. (SCON), Pfizer Inc. (PFE), ACADIA Pharmaceuticals Inc. (ACAD):... Mar 25 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of... Mar 25 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Mar 25 2015
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against ACADIA... Mar 24 2015
Hagens Berman Alerts ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD) Investors With Over $100,000 in... Mar 23 2015
ACADIA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... Mar 20 2015
The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press... Mar 19 2015
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000... Mar 18 2015
Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Analyst Blog Mar 18 2015
ACADIA Pharmaceuticals Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor... Mar 18 2015
Deadline in Lawsuit for Investors in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Announced by... Mar 18 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Mar 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK